Tirzepatide Explored for Pre-Surgical Weight Loss in Prostate Cancer Patients

Obesity and being overweight are significant risk factors for various cancers, including prostate cancer, and can complicate surgical outcomes and recovery. Reducing body weight before major surgery like a radical prostatectomy (surgical removal of the prostate gland) could potentially improve patient prognosis and reduce complications. While tirzepatide is a potent dual GLP-1 and GIP receptor agonist known for its significant weight loss effects, the feasibility of using a tirzepatide-assisted weight loss program specifically before radical prostatectomy in men with intermediate-risk prostate cancer remains an unaddressed clinical question.

As this is a recruiting study, no clinical results are available yet regarding patient outcomes. However, the primary objectives outline the specific feasibility targets this program aims to achieve. These metrics will determine if a larger, efficacy-focused trial is warranted, providing crucial data on the operational aspects of integrating tirzepatide into pre-surgical oncology care. The focus is on demonstrating that such a program can be successfully implemented in this specific patient population. The study defines successful feasibility as achieving 30 patient accrual within 2 years, with ≥90% retention through the day of surgery, and ≥70% adherence to study sessions and clinic visits. These ambitious targets highlight the commitment to ensuring patient compliance and logistical success, which are critical for any new therapeutic strategy.